X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Support and Resistance / Dechra Pharmaceuticals PLC (DPH.L) 10-03-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Dechra Pharmaceuticals PLC (DPH.L) 10-03-20

Will Dechra Pharmaceuticals PLC (DPH.L) shares break below the 2596p support, or return to highs of 3036p (+17%)?

 

  • Currently close to the 2596p support at 2586p (at time of writing).
  • This has been identified for ostensibly strong support level. Traders should consider whether they think it will hold up again.
  • Will the price bounce again to recent highs at 3036p? (+17%).
  • Technical traders should consider potential news and developments. Check our website and the press for updates in future.
  • Shares -15% from 12-month highs; +9% from 12 month lows.

Latest News

25 Feb:  JP Morgan Cazenove reiterates its overweight rating on Dechra Pharmaceuticals (DPH) and increased the target price to 3300p (from 3200p).

 

24 Feb:  Dechra Pharmaceuticals, the veterinary pharmaceuticals group,  announced that H1 profit grew by more than 100%, driven by ‘strong’ revenue Europe. However, the company cautioned investors of supply issues in North America.

21 Jan:  Jefferies International has downgraded its rating on Dechra Pharmaceuticals (DPH) to hold (from buy) and reduced the target price to 2930p (from 3090p).

16 Jan:  Dechra Pharmaceuticals announced that the full-year’s performance would be weighted more to the second half, which is unusual.

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

 

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.